BioMarin Pharmaceutical

Últimas noticias

Titulares en el idioma original de la fuente.

• What BioMarin Pharmaceutical (BMRN)'s AI Drug Discovery Deal Means For Shareholders (se abre en una pestaña nueva)

  Simply Wall Street · 2 oct 2026

• After 4,086 shares were delivered or withheld, BioMarin (BMRN) R&D chief holds 47,732 shares. (se abre en una pestaña nueva)

  Stock Titan · 1 oct 2026

• BioMarin Pharmaceutical Inc. (BMRN) Stock Price, News, Quote & History (se abre en una pestaña nueva)

  Yahoo! Finance Canada · 1 oct 2026

• The Strategic Financial Case for BioMarin Pharmaceutical (BMRN) (se abre en una pestaña nueva)

  Yahoo Finance · 1 oct 2026

• BioMarin and Profluent partner on AI-designed enzyme therapies (se abre en una pestaña nueva)

  Pharmaceutical Technology · 1 oct 2026

• BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration (se abre en una pestaña nueva)

  Simply Wall Street · 1 oct 2026

• BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth (se abre en una pestaña nueva)

  AD HOC NEWS · 30 sept 2026

• Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026 (se abre en una pestaña nueva)

  TradingView · 30 sept 2026

• BioMarin Grants Ascendis Global License, Secures Royalty Revenues (se abre en una pestaña nueva)

  tipranks.com · 30 sept 2026

• BioMarin Licenses CNP IP to Ascendis; 20% US, 18% EU/Brazil/S. Korea Royalties Until May 2030 (se abre en una pestaña nueva)

  TradingView · 30 sept 2026

• BioMarin lays off 117 California workers to consolidate footprint (se abre en una pestaña nueva)

  Fierce Pharma · 30 sept 2026

• Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI (se abre en una pestaña nueva)

  marketscreener.com · 30 sept 2026

• Profluent Partners With BioMarin to Design Novel Medicines Using AI (se abre en una pestaña nueva)

  Business Wire · 30 sept 2026

• Layoff Tracker: Novo, BioMarin, Enanta dole out pink slips (se abre en una pestaña nueva)

  BioSpace · 30 sept 2026

• BioMarin Pharmaceutical (BMRN) Adds Robert Plenge To Its Board (se abre en una pestaña nueva)

  Simply Wall Street · 26 sept 2026

• BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish (se abre en una pestaña nueva)

  AD HOC NEWS · 23 sept 2026

• BioMarin Pharmaceutical stock holds near its 52-week low (se abre en una pestaña nueva)

  AD HOC NEWS · 22 sept 2026

• BioMarin: Why I See Significant Upside Into 2027 (NASDAQ:BMRN) (se abre en una pestaña nueva)

  Seeking Alpha · 21 sept 2026

• BioMarin Pharmaceutical stock holds near a $12.38 billion value (se abre en una pestaña nueva)

  AD HOC NEWS · 20 sept 2026

• What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)? (se abre en una pestaña nueva)

  Yahoo Finance · 19 sept 2026

• BioMarin stock steadies after September 17 close (se abre en una pestaña nueva)

  AD HOC NEWS · 18 sept 2026

• BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone (se abre en una pestaña nueva)

  Yahoo Finance · 18 sept 2026

• What BioMarin Pharmaceutical Shares' Phase 3 Growth Data Means For Shareholders (se abre en una pestaña nueva)

  Simply Wall Street · 17 sept 2026

• BioMarin Pharmaceutical Grants Director Robert M Plenge 6,140 Shares at No Cost (NASDAQ: BMRN) (se abre en una pestaña nueva)

  Kalkine Media · 15 sept 2026

• BioMarin drops Voxzogo development for Noonan syndrome as treatment landscape shifts (se abre en una pestaña nueva)

  Fierce Pharma · 15 sept 2026

• BioMarin's stock target raised to $97 after pos... (se abre en una pestaña nueva)

  Pluang · 15 sept 2026

• Form 8K Biomarin Pharmaceutical Inc For: 14 September By Investing.com (se abre en una pestaña nueva)

  Investing.com India · 14 sept 2026

• BioMarin Appoints Bristol Myers Squibb Research Chief Robert Plenge to Board (se abre en una pestaña nueva)

  citybiz.co · 14 sept 2026

• BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors (se abre en una pestaña nueva)

  PR Newswire · 14 sept 2026

• BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Appoints BMS R&D Chief Robert Plenge to Board (se abre en una pestaña nueva)

  TradingView · 14 sept 2026